Ppgl Initial Screening Test Selection

Initial PPGL Biochemical Screening Test Selection

STEP 1 — Gather Information

Collect clinical triggers (symptoms, incidental adrenal mass), assess availability of random urinary fractionated metanephrines (creatinine-corrected), blood fractionated catecholamines, and plasma-free fractionated metanephrines; review medications and foods per Table 3 that may interfere; evaluate renal function for creatinine correction if urine test considered.
→ Determine which test is feasible and appropriate for initial screening.

STEP 2 — Rule In / Rule Out

Perform the selected initial screening test. If random urinary fractionated metanephrines (creatinine-corrected) >3× upper limit of normal, or blood fractionated catecholamines >3× upper limit, or plasma-free fractionated metanephrines > upper limit, then screen positive (rule in PPGL); otherwise screen negative (rule out PPGL).
→ Proceed to classification based on screen result.

STEP 3 — Classify or Stratify

If screen positive, proceed to confirmatory testing with 24-hour urinary fractionated metanephrines (or catecholamines) or plasma-free fractionated metanephrines per I-2-3; if screen negative but clinical suspicion remains high, repeat screening with an alternative sample type or consider clinical follow-up; if screen negative and low suspicion, consider alternative diagnoses.
→ Decide on next diagnostic action.

STEP 4 — Decide

For screen-positive patients, order confirmatory biochemical tests and arrange imaging per I-3; for screen-negative patients with low suspicion, discharge from PPGL workup; for screen-negative patients with high suspicion, repeat testing or seek specialist consultation.
→ Initiate appropriate follow‑up pathway.

Clinical Guardrails / Mimics / Pitfalls

Avoid testing during acute stress, after caffeine, nicotine, or tyramine‑rich foods; discontinue interfering medications (e.g., tricyclic antidepressants, decongestants) per Table 3; false positives common in critically ill or stressed patients; false negatives may occur with severe renal impairment affecting creatinine correction; plasma‑free fractionated metanephrines limited to one measurement under Japanese health insurance for differential diagnosis; ensure proper sample handling (fasting, supine rest 20–30 min, immediate freezing) to prevent degradation.

Concrete Clinical Example

A 46‑year‑old woman presents with episodic palpitations and hypertension; an incidental 1.5 cm left adrenal nodule is found on abdominal CT. She reports no interfering medications and avoids caffeine. Random urinary fractionated metanephrines, corrected for creatinine, returns at 3.8× the upper limit of normal. Screening test is positive, prompting 24‑hour urinary fractionated metanephrines for confirmation.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165